Genmab A/S Competitors

Zoetis (NYSE:ZTS) and Genmab A/S (NASDAQ:GMAB) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Institutional & Insider Ownership

92.5% of Zoetis shares are held by institutional investors. Comparatively, 6.2% of Genmab A/S shares are held by institutional investors. 0.2% of Zoetis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk & Volatility

Zoetis has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Zoetis and Genmab A/S, as provided by MarketBeat.

Zoetis currently has a consensus price target of $170.0833, suggesting a potential upside of 1.46%. Genmab A/S has a consensus price target of $42.1429, suggesting a potential upside of 19.62%. Given Genmab A/S's higher probable upside, analysts clearly believe Genmab A/S is more favorable than Zoetis.

Profitability

This table compares Zoetis and Genmab A/S's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Zoetis and Genmab A/S's top-line revenue, earnings per share and valuation.

Zoetis has higher revenue and earnings than Genmab A/S. Zoetis is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Summary

Zoetis beats Genmab A/S on 9 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Genmab A/S (NASDAQ:GMAB) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Institutional and Insider Ownership

92.2% of Vertex Pharmaceuticals shares are held by institutional investors. Comparatively, 6.2% of Genmab A/S shares are held by institutional investors. 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Vertex Pharmaceuticals and Genmab A/S, as provided by MarketBeat.

Vertex Pharmaceuticals currently has a consensus price target of $293.1250, suggesting a potential upside of 33.61%. Genmab A/S has a consensus price target of $42.1429, suggesting a potential upside of 19.62%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Genmab A/S.

Profitability

This table compares Vertex Pharmaceuticals and Genmab A/S's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Vertex Pharmaceuticals and Genmab A/S's top-line revenue, earnings per share and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Genmab A/S. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Summary

Vertex Pharmaceuticals beats Genmab A/S on 10 of the 15 factors compared between the two stocks.

Takeda Pharmaceutical (NYSE:TAK) and Genmab A/S (NASDAQ:GMAB) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Institutional and Insider Ownership

3.4% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 6.2% of Genmab A/S shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Takeda Pharmaceutical has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Takeda Pharmaceutical and Genmab A/S, as provided by MarketBeat.

Genmab A/S has a consensus price target of $42.1429, suggesting a potential upside of 19.62%. Given Genmab A/S's stronger consensus rating and higher possible upside, analysts plainly believe Genmab A/S is more favorable than Takeda Pharmaceutical.

Profitability

This table compares Takeda Pharmaceutical and Genmab A/S's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Takeda Pharmaceutical and Genmab A/S's top-line revenue, earnings per share and valuation.

Takeda Pharmaceutical has higher revenue and earnings than Genmab A/S. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Summary

Genmab A/S beats Takeda Pharmaceutical on 8 of the 13 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Genmab A/S (NASDAQ:GMAB) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Institutional and Insider Ownership

85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. Comparatively, 6.2% of Genmab A/S shares are held by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Regeneron Pharmaceuticals and Genmab A/S's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Regeneron Pharmaceuticals and Genmab A/S, as provided by MarketBeat.

Regeneron Pharmaceuticals currently has a consensus price target of $646.2609, suggesting a potential upside of 28.58%. Genmab A/S has a consensus price target of $42.1429, suggesting a potential upside of 19.62%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Genmab A/S.

Earnings and Valuation

This table compares Regeneron Pharmaceuticals and Genmab A/S's top-line revenue, earnings per share and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Genmab A/S. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Regeneron Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500.

Summary

Regeneron Pharmaceuticals beats Genmab A/S on 9 of the 15 factors compared between the two stocks.

Genmab A/S (NASDAQ:GMAB) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, analyst recommendations, risk, dividends and valuation.

Insider & Institutional Ownership

6.2% of Genmab A/S shares are owned by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Genmab A/S and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings and target prices for Genmab A/S and Alexion Pharmaceuticals, as reported by MarketBeat.

Genmab A/S presently has a consensus target price of $42.1429, suggesting a potential upside of 19.62%. Alexion Pharmaceuticals has a consensus target price of $153.8636, suggesting a potential downside of 6.00%. Given Genmab A/S's stronger consensus rating and higher possible upside, equities research analysts plainly believe Genmab A/S is more favorable than Alexion Pharmaceuticals.

Earnings & Valuation

This table compares Genmab A/S and Alexion Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Genmab A/S. Alexion Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Genmab A/S has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.

Summary

Alexion Pharmaceuticals beats Genmab A/S on 8 of the 15 factors compared between the two stocks.

Genmab A/S (NASDAQ:GMAB) and BeiGene (NASDAQ:BGNE) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, analyst recommendations, risk, dividends and valuation.

Insider & Institutional Ownership

6.2% of Genmab A/S shares are owned by institutional investors. Comparatively, 60.7% of BeiGene shares are owned by institutional investors. 9.0% of BeiGene shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Genmab A/S and BeiGene's net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of current ratings and target prices for Genmab A/S and BeiGene, as reported by MarketBeat.

Genmab A/S presently has a consensus target price of $42.1429, suggesting a potential upside of 19.62%. BeiGene has a consensus target price of $319.3750, suggesting a potential upside of 4.53%. Given Genmab A/S's higher possible upside, equities research analysts plainly believe Genmab A/S is more favorable than BeiGene.

Earnings & Valuation

This table compares Genmab A/S and BeiGene's gross revenue, earnings per share (EPS) and valuation.

Genmab A/S has higher revenue and earnings than BeiGene. BeiGene is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Genmab A/S has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500. Comparatively, BeiGene has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500.

Summary

Genmab A/S beats BeiGene on 10 of the 14 factors compared between the two stocks.